Access to CAR T-Cell Therapy

Minority Access & Outcomes with Anti-BCMA CAR T Therapy in #Myeloma | Luca Paruzzo, MD | #ASH24Подробнее

CAR T-cell therapy in triple-class refractory myelomaПодробнее

Reflecting on 5 years cancer-free: Charlotte's CAR T storyПодробнее

Session 4 : CART cellsПодробнее

Being more selective when choosing myeloma candidates for CAR-T therapy due to capacity issuesПодробнее

Assessing financial toxicity of CAR-T therapy in myeloma and improving access to this treatmentПодробнее

Personalised place-of-care manufactured immune cells for blood cancerПодробнее

CAR T-Cell Therapy for Myeloma | Challenges and Unmet NeedsПодробнее

Improving global access to novel immunotherapies for patients with R/R DLBCLПодробнее

Dr. Mikhael on Unanswered Questions in CAR-TПодробнее

How Can Myeloma Patients Access CAR T-Cell Therapy Clinical Trials?Подробнее

A Look at Promising Strategies to Improve CAR T-Cell Therapy AccessПодробнее

CAR T-cell therapy programs to improve access for patients with leukemia in MexicoПодробнее

How to identify reliable information on CAR T-cell therapy onlineПодробнее

How to Access Life-Saving Cancer Treatments in MexicoПодробнее

CAR T-Cell Therapy Development in IndiaПодробнее

CAR T-cell Therapy in Myeloma: What to Expect and Late EffectsПодробнее

What Is the Impact of CAR T-Cell Therapy Access Barriers on Patients?Подробнее

The patient pathway to survival in second line DLBCL: improving access to CAR-TПодробнее

Ethical Considerations in CAR T-cell TherapyПодробнее